Page 23 - Mployee Wellness Programs News Today

In navigating fiscal uncertainties, it is essential to acknowledge technology as a powerful ally, securing the resilience and long-term sustainability of home care for generations of patients and caregivers to follow.

Hospitals weathered one of their most challenging years in 2022, with median operating margins staying in the red throughout most of the year. Those money problems proved to be a major factor shaping last year’s M&A transactions — financial pressures influenced 28% of hospital M&A deals last year, up from 15% in 2022, a new report showed.

AI, health equity and merger and acquisition activity are among the trends to watch in 2024, according to a recent report from Deloitte.

Innovation in the HIV treatment landscape is playing a role in addressing medication adherence. In recent years, long-acting injectable antiretroviral monthly and bi-monthly treatment options have been approved – a welcome alternative for people living with HIV. We are now on the cusp of it coming full circle from the days when patients took multiple pills a day to potentially a one-and-done single-dose treatment

By adopting integrated care models, providers and payors can ensure a seamless continuum of care for older adults.

The psychiatric collaborative care model offers an opportunity to mitigate burnout by reducing the burden placed on primary care providers (PCPs) and more effectively supporting their patients with behavioral health needs.

TBD Health is moving into the B2B healthcare space by partnering with digital health companies, starting with FOLX Health and Wisp.

During a panel discussion at CES 2024, health executives shared safe ways AI can be used to support value-based care. This includes automating tasks and predicting who needs additional care.

BridgeBio will receive $500 million in exchange for royalties from sales of acoramidis, a drug currently under FDA review for treating heart complications caused by the rare disease transthyretin amyloidosis. The deal also refinances lending agreements, providing BridgeBio with access to additional capital.

The former Pfizer statistician worked on the clinical trial for the Covid-19 drug Paxlovid. A jury found the employee guilty of insider trading for transactions made before clinical data for the antiviral were publicly announced.